All Stories

  1. Advancing in precision asthma management: The Treat-to-Target by Treatable Traits (T4) framework
  2. Effect of Delayed Initiation of Mepolizumab on EXACTO Scale Scores, Clinical Remission SEPAR-REMAS Criteria, and Functional Outcomes in Uncontrolled Severe Asthma: A Real-World Study
  3. Monitoring Lung Function of Asthmatic Swimmers in Public Swimming Pools
  4. Effect of Delayed Initiation of Mepolizumab on Exacto Scale Scores, Clinical Remission Separ-Remas Criteria, and Functional Outcomes in Uncontrolled Severe Asthma: A Real-World Study
  5. Clinical utility of oscillometry for assessing pulmonary function in asthmatic pregnant women with contraindications to spirometry
  6. Evaluation of the SEPAR-ALAT Asthma Exacerbation Severity Classification
  7. Peak Inspiratory Flow Capability for Simulated Dry Powder Inhaler Resistances in Asthma Patients Prescribed Pressurized Metered-Dose Inhalers with Valved Holding Chambers: The USE-DPI Study
  8. Specialized asthma care units in Spain: limited awareness; strong support
  9. Longitudinal Evolution of Phenotypes in Severe Asthma: Clinical Implications for Personalized Medicine
  10. Prevalence of Asthma and Associated Comorbidities in the Spanish Population: A Cross-sectional Survey
  11. Effectiveness of Mepolizumab and Dupilumab in patients with asthma-COPD overlap (ACO) compared to severe uncontrolled asthma (SUA): A retrospective observational cohort study
  12. Effectiveness of Mepolizumab in Severe Uncontrolled Asthma Associated or Not with EGPA Based on the Exacto Scale and Separ-Remas Criteria
  13. Estudio de coste utilidad de una consulta de alta resolución (CARE-A) para el tratamiento de exacerbaciones de asma
  14. Temporal Trends in Baseline Severity and 12-Month Response to Mepolizumab in Severe Asthma: The TYREX Multicentre Real-World Study in Spain (2017–2024)
  15. <b>Consenso ALAT-SEPAR sobre la definición y clasificación de las exacerbaciones del asma según su gravedad: hacia una estandarización internacional</b>
  16. News From the Severe Asthma Consensus 2025 Review
  17. Real-world use of beclometasone dipropionate and formoterol fumarate NEXThaler® and asthma control among adult asthmatic patients in Europe: The results of the Newton study
  18. ALAT-SEPAR Consensus on the Definition and Classification of Asthma Exacerbations by Severity: A Move Toward International Standardization
  19. FEV1 decline and clinical predictors in asthma after 10 Years of follow-up: BMI as a modifiable risk factor
  20. Documento de consenso de asma grave. Actualización 2025
  21. Identification of Fractional Exhaled Nitric Oxide Cutoff Values for the Diagnosis of Asthma
  22. Effectiveness of treatment with Mepolizumab and Dupilumab in Patients with Asthma and COPD overlap (ACO) compared to Patients with Uncontrolled Severe Asthma Without COPD
  23. Reply to Letter: The Importance of Multidisciplinary Teams in the Evaluation of the Remission of Chronic Rhinosinusitis in Severe Asthma
  24. Disease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus)
  25. Spanish Consensus on Remission in Asthma (REMAS)
  26. General versus domain‐specific grit in the work context
  27. The effect of biologics in lung function and quality of life of patients with united airways disease: A systematic review
  28. Therapeutic Goals and Treatable Traits: Long-Term Trends in a Severe Asthma Population
  29. Understanding Severe Asthma Through Small and Big Data in Spanish Hospitals: The PAGE Study
  30. Necesidades no cubiertas en asma alérgica grave
  31. Quality indicators in the rational management of severe asthma: A Spanish multidisciplinary consensus
  32. Evaluation of Different Doses in Inhaled Therapy: A Comprehensive Analysis
  33. Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain
  34. Estudio de prevalencia de asma en población general en España
  35. What's New in the 2022 Consensus for Severe Asthma in Adults
  36. Evaluation of the Diagnostic Accuracy of Non-Specific Bronchial Provocation Tests in the Diagnosis of Asthma: A Randomized Cross-Over Study
  37. Human Resources Analytics: A systematic Review from a Sustainable Management Approach
  38. Documento de consenso de asma grave en adultos. Actualización 2022
  39. Documento de consenso de expertos para el control del asma en personas mayores
  40. Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
  41. El asma en las personas mayores también existe
  42. [Translated article] Asthma Exists in Older People too
  43. Referral Criteria for Asthma and the Pandemic: New Challenges, New Responses
  44. Criterios de derivación en asma: Actualización documento de consenso
  45. Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map
  46. Documento de consenso sobre asma y tabaquismo del Foro Autonómico de Asma de la SEPAR
  47. Asthma control and adherence to clinical practice guidelines: mission impossible?
  48. Preference for Easyhaler® Over Previous Dry Powder Inhalers in Asthma Patients: Results of the DPI PREFER Observational Study
  49. Documento de consenso de enfermería en asma 2020
  50. <p>A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future</p>
  51. La termoplastia en el punto de mira
  52. Documento de consenso de asma grave en adultos. Actualización 2020
  53. Control del asma y seguimiento de las guías de práctica clínica: ¿misión imposible?
  54. El manejo del asma como enfermedad inflamatoria crónica y problema sanitario global: documento de posicionamiento de las sociedades científicas
  55. Functional Endoscopic Sinus Surgery for Nasal Polyposis in Asthma Patients: Impact on Bronchial Inflammation
  56. PAGE Study: Summary of a study protocol to estimate the prevalence of severe asthma in Spain using big-data methods
  57. Referral Criteria for Asthma: Consensus Document
  58. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
  59. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study
  60. Rinitis, poliposis nasal y su relación con el asma
  61. Dilemmas and New Paradigms in Asthma Management
  62. Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study
  63. Anxiety, Depression, and Asthma Control: Changes After Standardized Treatment
  64. Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate–severe asthma
  65. Consensus on the Asthma–COPD Overlap (ACO) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA)
  66. Predictive factors for moderate or severe exacerbations in asthma patients receiving outpatient care
  67. Algorithm for identification of asthma–COPD overlap: consensus between the Spanish COPD and asthma guidelines
  68. Is the bronchodilator test an useful tool to measure asthma control?
  69. Quality Indicators of Asthma Care Derived From the Spanish Guidelines for Asthma Management (GEMA 4.0): A Multidisciplinary Team Report
  70. Predictors of 10-year smoking abstinence in smokers abstinent for 1 year after treatment
  71. Comparative study of bronchial provocation tests using methacholine or mannitol in bronchial asthma
  72. de Torres JP
  73. Guidelines for the Study of Nonspecific Bronchial Hyperresponsiveness in Asthma
  74. Normativa sobre el estudio de la hiperrespuesta bronquial inespecífica en el asma
  75. Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry
  76. Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches
  77. Measurement of asthma control according to global initiative for asthma guidelines: a comparison with the asthma control questionnaire
  78. Documento de consenso sobre enfermedad pulmonar obstructiva crónica en Andalucía-2010
  79. Factors Predicting the Initiation of a Tobacco Cessation Program in Spain
  80. Neumonías adquiridas en la comunidad
  81. Protocolo de tratamiento empírico de las neumonías adquiridas en la comunidad
  82. Protocolo de tratamiento empírico de las neumonías nosocomiales
  83. Indicaciones e interpretación clínica del cultivo de esputo. Lavado bronquial
  84. Indicaciones e interpretación clínica de la prueba de la tuberculina. Quimioprofilaxis
  85. Tuberculosis pulmonar
  86. Premenstrual Asthma and Symptoms Related to Premenstrual Syndrome
  87. Premenstrual asthma and atopy markers
  88. Relación del test de control del asma (ACT) con la función pulmonar, niveles de óxido nítrico exhalado y grados de control según la Iniciativa Global para el Asma (GINA)
  89. Relationship of the Asthma Control Test (ACT) with Lung Function, Levels of Exhaled Nitric Oxide and Control According to the Global Initiative for Asthma (GINA)
  90. Variability in the prevalence of premenstrual asthma
  91. Documento de Consenso sobre la espirometría en Andalucía
  92. Documento de Consenso en Andalucía: enfermedad pulmonar obstructiva crónica
  93. Impact of Chronic Obstructive Pulmonary Disease on Activities of Daily Living: Results of the Multicenter EIME Study
  94. Impacto de la EPOC en la vida diaria de los pacientes. Resultados del estudio multicéntrico EIME
  95. Atención y prestación de servicios en materia de tabaquismo
  96. Exacerbations, Hospital Admissions and Impaired Health Status in Chronic Obstructive Pulmonary Disease
  97. Segundo documento de consenso sobre uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica
  98. Respuesta de los autores
  99. Una opinión contraria al incremento del número de cirujanos torácicos
  100. F.J. Álvarez Gutiérrez
  101. Distribución de neumólogos y cirujanos torácicos en España
  102. Neumonías adquiridas en la comunidad en pacientes mayores de 60 años. Incidencia de gérmenes atípicos y evolución clinicorradiológica
  103. Estudio prospectivo de 221 neumonías adquiridas en la comunidad seguidas de forma ambulatoria. Etiología y evolución clinicorradiológica
  104. Cartas al Editor
  105. Investigation of Tuberculosis Contacts in a Nonhospital Pneumology Practice
  106. Mediadores de la inflamación (proteína catiónica del eosinófilo, ECP) en población normal y pacientes con asma bronquial o rinitis alérgica